Quest Diagnostics Inc (DGX) 85.65 $DGX
Quest Diagnostics and AncestryDNA Collaborate to Expand Consumer DNA Testing
PR Newswire - Wed Aug 03, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and AncestryDNA, the leader in family history and consumer genomics, are teaming up to help meet the rapidly growing consumer demand for genetic tests that provide insights into genetic ethnicity, origins and other factors. The new collaboration will allow AncestryDNA to scale its testing services and pave the way for new wellness offerings.
DGX: 85.65 (+0.41)
Quest Diagnostics Up 30.0% Since SmarTrend Uptrend Call (DGX)
Comtex SmarTrend(R) - Tue Aug 02, 1:17PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 30.04% as of today's recent price of $84.99.
DGX: 85.65 (+0.41)
Data Diagnostics Healthcare Technology Wins Two Gold Honors for Innovation in the 2016 Golden Bridge Awards
PR Newswire - Wed Jul 27, 12:31PM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two gold medals at the 2016 Golden Bridge Awards. The solution earned gold in the categories of New Product, Service, Upgrade, or Innovation of the Year and Innovations in Technology. The annual Golden Bridge Awards are an industry and peer recognition program honoring the world's best products, services and companies.
DGX: 85.65 (+0.41), INOV: 19.27 (+0.62)
Healthcare Q2 Earnings to Watch this Week: UNH, DGX, ADPT
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 9:01AM CDT
Health insurers are expected to see top-line growth on an increase in member enrollment. Laboratory and diagnostic services is expected to see earnings accretion.
DGX: 85.65 (+0.41), UNH: 142.88 (-0.29), ADPT: 44.80 (+1.08)
Will Quest Diagnostics' (DGX) Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 4:16PM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its first-quarter 2016 earnings results before the opening bell on Jul 21, 2016.
AMSG: 72.31 (+0.27), HCA: 75.71 (+0.67), DGX: 85.65 (+0.41), COO: 181.30 (-0.67)
Apollo Enters Agreement with ChartMaxx(R) from Quest Diagnostics to Provide Enterprise Imaging and Content Management Technology
PRWeb - Wed Jul 13, 1:09PM CDT
Apollo Enterprise Imaging Corp, the pioneer in enterprise imaging and clinical multimedia management solutions, today announced that it has entered into a strategic agreement with Quest Diagnostics to provide a complete enterprise imaging and content management solution for use with ChartMaxx(R), an enterprise content management (ECM) solution from Quest Diagnostics. With the combined solution, hospitals and health systems that use ChartMaxx will be able to manage, retrieve and share a broader spectrum of clinical multimedia, images, documents and data within the ChartMaxx platform. Additional terms were not disclosed.
DGX: 85.65 (+0.41)
Quest Diagnostics Estimates Move Up, Tie-Ups to Add Value
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:31AM CDT
On Jul 11, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
AMSG: 72.31 (+0.27), HCA: 75.71 (+0.67), DGX: 85.65 (+0.41), BIOS: 2.61 (+0.10)
Quest Diagnostics Shares Up 25.2% Since SmarTrend's Buy Recommendation (DGX)
Comtex SmarTrend(R) - Fri Jul 08, 1:35PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSEGX) on February 18th, 2016 at $65.35. In approximately 5 months, Quest Diagnostics has returned 25.19% as of today's recent price of $81.82.
DGX: 85.65 (+0.41)
Shares of DGX Up 22.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 23, 1:45PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSEGX) on February 18th, 2016 at $65.35. In approximately 4 months, Quest Diagnostics has returned 22.59% as of today's recent price of $80.12.
DGX: 85.65 (+0.41)
Quest Diagnostics Rises 2.32% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 22, 12:11PM CDT
Quest Diagnostics (NYSEGX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DGX: 85.65 (+0.41)
Watch for Quest Diagnostics to Potentially Pullback After Gaining 2.32% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 12:09PM CDT
Quest Diagnostics (NYSEGX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DGX: 85.65 (+0.41)
Quest Diagnostics to Relocate Headquarters to 500 Plaza Drive in Secaucus, NJ
PR Newswire - Mon Jun 20, 4:00AM CDT
Marcus Partners, a value-oriented real estate investor, announced today that Quest Diagnostics Incorporated, (NYSE: DGX), the world's leading provider of diagnostic information services, has signed a 130,200 square foot long term lease on the top four floors of 500 Plaza Drive in Secaucus, NJ, which will serve as the company's new headquarters location.
DGX: 85.65 (+0.41)
Look for Shares of Quest Diagnostics to Potentially Rebound after Yesterday's 1.74% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 1:48PM CDT
Quest Diagnostics (NYSEGX) traded in a range yesterday that spanned from a low of $75.20 to a high of $77.27. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $75.89 on volume of 780,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DGX: 85.65 (+0.41)
Data Diagnostics Healthcare Technology Wins Two 2016 IT World Awards
PR Newswire - Thu Jun 09, 7:00AM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two IT World Awards®. The solution earned a gold medal in the IT Products and Services for Healthcare category and a bronze medal for New Products and Services. Other companies to win awards in the New Products and Services category include Dell and Samsung. The Network Products Guide's IT World Awards are provided annually to honor achievement in all facets of the information technology industry.
DGX: 85.65 (+0.41), INOV: 19.27 (+0.62)
Quest Diagnostics to Relocate Corporate Headquarters, Consolidate Office Facilities, in New Jersey
PR Newswire - Mon Jun 06, 5:45AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will relocate its corporate headquarters from Madison, N.J. to Secaucus, N.J. when its lease expires in September 2017.
DGX: 85.65 (+0.41)
Fit Female College Athletes More Prone to Overreaching than Less Fit Ones, Putting Performance at Risk, Finds New Research Presented at American College of Sports Medicine Annual Meeting
PR Newswire - Thu Jun 02, 12:24PM CDT
Female college athletes at their highest pre-season fitness levels may be more susceptible to overreach in a team sport environment than less fit ones, according to original research being presented at the American College of Sports Medicine Annual (ACSM) Meeting.
DGX: 85.65 (+0.41)
Quest Diagnostics To Speak At The Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 8:10AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 2016 Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, June 7, 2016 at 11:40 a.m. Eastern Time.
DGX: 85.65 (+0.41)
One Year After Launch, BRCA Share(TM) Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk
PR Newswire - Wed Jun 01, 7:11AM CDT
BRCA Share, a public-private BRCA gene datashare initiative, today announced the public release of a large collection of new data on genetic variants in the BRCA1 and BRCA2 genes. Mutations of these genes raise the risk of breast, ovarian and other cancers. The findings are to be presented today at the 6th International Biennial Meeting of Human Variome Project Consortium (HVP6) held at UNESCO headquarters in Paris.
DGX: 85.65 (+0.41), LH: 140.13 (+0.75)
Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals
PR Newswire - Tue May 31, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the HealthONE System of HCA Healthcare (NYSE: HCA) are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through an agreement for Quest to manage in-patient laboratory operations for six Denver-area hospitals in the HealthONE system.
HCA: 75.71 (+0.67), DGX: 85.65 (+0.41)
Quest Diagnostics Launches Three Genetic Test Panels for Predicting Hereditary Cancer Risk
PR Newswire - Thu May 26, 10:54AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of three new cancer test services designed to provide clinically actionable insight into an individual's risk of developing hereditary forms of cancer. Part of the company's newly branded Quest Vantage(TM) cancer test menu, the tests and accompanying services are designed to provide physicians and patients with clinically actionable data and related support capabilities, including results interpretation, access to genetic counseling and prior authorization for health plan reimbursement.
DGX: 85.65 (+0.41)
Quest Diagnostics and AncestryDNA Collaborate to Expand Consumer DNA Testing
PR Newswire - Wed Aug 03, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and AncestryDNA, the leader in family history and consumer genomics, are teaming up to help meet the rapidly growing consumer demand for genetic tests that provide insights into genetic ethnicity, origins and other factors. The new collaboration will allow AncestryDNA to scale its testing services and pave the way for new wellness offerings.
DGX: 85.65 (+0.41)
Quest Diagnostics Up 30.0% Since SmarTrend Uptrend Call (DGX)
Comtex SmarTrend(R) - Tue Aug 02, 1:17PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 30.04% as of today's recent price of $84.99. DGX: 85.65 (+0.41)
Data Diagnostics Healthcare Technology Wins Two Gold Honors for Innovation in the 2016 Golden Bridge Awards
PR Newswire - Wed Jul 27, 12:31PM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two gold medals at the 2016 Golden Bridge Awards. The solution earned gold in the categories of New Product, Service, Upgrade, or Innovation of the Year and Innovations in Technology. The annual Golden Bridge Awards are an industry and peer recognition program honoring the world's best products, services and companies.
DGX: 85.65 (+0.41), INOV: 19.27 (+0.62)
Healthcare Q2 Earnings to Watch this Week: UNH, DGX, ADPT
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 9:01AM CDT
Health insurers are expected to see top-line growth on an increase in member enrollment. Laboratory and diagnostic services is expected to see earnings accretion.
DGX: 85.65 (+0.41), UNH: 142.88 (-0.29), ADPT: 44.80 (+1.08)
Will Quest Diagnostics' (DGX) Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 4:16PM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its first-quarter 2016 earnings results before the opening bell on Jul 21, 2016.
AMSG: 72.31 (+0.27), HCA: 75.71 (+0.67), DGX: 85.65 (+0.41), COO: 181.30 (-0.67)
Apollo Enters Agreement with ChartMaxx(R) from Quest Diagnostics to Provide Enterprise Imaging and Content Management Technology
PRWeb - Wed Jul 13, 1:09PM CDT
Apollo Enterprise Imaging Corp, the pioneer in enterprise imaging and clinical multimedia management solutions, today announced that it has entered into a strategic agreement with Quest Diagnostics to provide a complete enterprise imaging and content management solution for use with ChartMaxx(R), an enterprise content management (ECM) solution from Quest Diagnostics. With the combined solution, hospitals and health systems that use ChartMaxx will be able to manage, retrieve and share a broader spectrum of clinical multimedia, images, documents and data within the ChartMaxx platform. Additional terms were not disclosed.
DGX: 85.65 (+0.41)
Quest Diagnostics Estimates Move Up, Tie-Ups to Add Value
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:31AM CDT
On Jul 11, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
AMSG: 72.31 (+0.27), HCA: 75.71 (+0.67), DGX: 85.65 (+0.41), BIOS: 2.61 (+0.10)
Quest Diagnostics Shares Up 25.2% Since SmarTrend's Buy Recommendation (DGX)
Comtex SmarTrend(R) - Fri Jul 08, 1:35PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 5 months, Quest Diagnostics has returned 25.19% as of today's recent price of $81.82. DGX: 85.65 (+0.41)
Shares of DGX Up 22.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 23, 1:45PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 4 months, Quest Diagnostics has returned 22.59% as of today's recent price of $80.12. DGX: 85.65 (+0.41)
Quest Diagnostics Rises 2.32% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 22, 12:11PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DGX: 85.65 (+0.41)
Watch for Quest Diagnostics to Potentially Pullback After Gaining 2.32% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 12:09PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DGX: 85.65 (+0.41)
Quest Diagnostics to Relocate Headquarters to 500 Plaza Drive in Secaucus, NJ
PR Newswire - Mon Jun 20, 4:00AM CDT
Marcus Partners, a value-oriented real estate investor, announced today that Quest Diagnostics Incorporated, (NYSE: DGX), the world's leading provider of diagnostic information services, has signed a 130,200 square foot long term lease on the top four floors of 500 Plaza Drive in Secaucus, NJ, which will serve as the company's new headquarters location.
DGX: 85.65 (+0.41)
Look for Shares of Quest Diagnostics to Potentially Rebound after Yesterday's 1.74% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 1:48PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $75.20 to a high of $77.27. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $75.89 on volume of 780,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. DGX: 85.65 (+0.41)
Data Diagnostics Healthcare Technology Wins Two 2016 IT World Awards
PR Newswire - Thu Jun 09, 7:00AM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two IT World Awards®. The solution earned a gold medal in the IT Products and Services for Healthcare category and a bronze medal for New Products and Services. Other companies to win awards in the New Products and Services category include Dell and Samsung. The Network Products Guide's IT World Awards are provided annually to honor achievement in all facets of the information technology industry.
DGX: 85.65 (+0.41), INOV: 19.27 (+0.62)
Quest Diagnostics to Relocate Corporate Headquarters, Consolidate Office Facilities, in New Jersey
PR Newswire - Mon Jun 06, 5:45AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will relocate its corporate headquarters from Madison, N.J. to Secaucus, N.J. when its lease expires in September 2017.
DGX: 85.65 (+0.41)
Fit Female College Athletes More Prone to Overreaching than Less Fit Ones, Putting Performance at Risk, Finds New Research Presented at American College of Sports Medicine Annual Meeting
PR Newswire - Thu Jun 02, 12:24PM CDT
Female college athletes at their highest pre-season fitness levels may be more susceptible to overreach in a team sport environment than less fit ones, according to original research being presented at the American College of Sports Medicine Annual (ACSM) Meeting.
DGX: 85.65 (+0.41)
Quest Diagnostics To Speak At The Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 8:10AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 2016 Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, June 7, 2016 at 11:40 a.m. Eastern Time.
DGX: 85.65 (+0.41)
One Year After Launch, BRCA Share(TM) Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk
PR Newswire - Wed Jun 01, 7:11AM CDT
BRCA Share, a public-private BRCA gene datashare initiative, today announced the public release of a large collection of new data on genetic variants in the BRCA1 and BRCA2 genes. Mutations of these genes raise the risk of breast, ovarian and other cancers. The findings are to be presented today at the 6th International Biennial Meeting of Human Variome Project Consortium (HVP6) held at UNESCO headquarters in Paris.
DGX: 85.65 (+0.41), LH: 140.13 (+0.75)
Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals
PR Newswire - Tue May 31, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the HealthONE System of HCA Healthcare (NYSE: HCA) are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through an agreement for Quest to manage in-patient laboratory operations for six Denver-area hospitals in the HealthONE system.
HCA: 75.71 (+0.67), DGX: 85.65 (+0.41)
Quest Diagnostics Launches Three Genetic Test Panels for Predicting Hereditary Cancer Risk
PR Newswire - Thu May 26, 10:54AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of three new cancer test services designed to provide clinically actionable insight into an individual's risk of developing hereditary forms of cancer. Part of the company's newly branded Quest Vantage(TM) cancer test menu, the tests and accompanying services are designed to provide physicians and patients with clinically actionable data and related support capabilities, including results interpretation, access to genetic counseling and prior authorization for health plan reimbursement.
DGX: 85.65 (+0.41)
